Updated Review of Treatment of Androgenetic Alopecia
Alopecia, a widespread issue affecting both genders, often manifests as androgenetic alopecia, although a thorough examination is needed to rule out other causes. This chapter focuses on the treatment of androgenetic alopecia. Finasteride and minoxidil, the Food and Drug Administration –approved treatments, offer stability and in some cases improvement in scalp coverage. Platelet-rich plasma exhibits positive results as an off-label alopecia therapy. For eligible individuals, hair transplantation proves effective, using healthy follicular units to restore hair-bearing areas. Mul tiple options allow for the tailoring of i...
Source: Facial Plastic Surgery Clinics of North America - March 28, 2024 Category: Cosmetic Surgery Authors: Roy Xiao, Linda N. Lee Source Type: research
Sexual dysfunction with 5-alpha-reductase inhibitor therapy for androgenetic alopecia: a global propensity score matched retrospective cohort study
(Source: Journal of the American Academy of Dermatology)
Source: Journal of the American Academy of Dermatology - March 27, 2024 Category: Dermatology Authors: Kyle C. Lauck, Allison Limmer, Peyton Harris, Dario Kivelevitch Source Type: research
Sacituzumab Govitecan for the treatment of advanced triple negative breast cancer patients: a multi-center real-world analysis
ConclusionThe results of this real-world analysis showed that both safety and efficacy of sacituzumab govitecan in mTNBC patients are consistent with that previously reported in regulatory trials. The use of premedication and supportive measures was associated with a satisfactory toxicity profile. (Source: Frontiers in Oncology)
Source: Frontiers in Oncology - March 26, 2024 Category: Cancer & Oncology Source Type: research
Correlating Cicatricial Alopecia and Cardiovascular Risk: Emerging Insights
The recent study published in this journal entitled “Association of Primary Cicatricial Alopecia with Subsequent Cardiovascular Disease” (Kim et al., 2023) adds new insights on the complex link between chronic inflammation of epithelial tissues and increased cardiovascular (CV) risk in patients with hair disorders. Primary Cicatricial Alopecia ( PCA) might not only be a dermatological condition, as systemic associations including autoimmune disorders such as thyroid diseases and vitiligo, metabolic syndrome, and, notably, CV risk can be part of the disease. (Source: Journal of Investigative Dermatology)
Source: Journal of Investigative Dermatology - March 26, 2024 Category: Dermatology Authors: Andrea Sechi, Antonella Tosti Tags: Commentary Source Type: research
A Case of Vitiligo Combined with Systemic Lupus Erythematosus Treated with Tofacitinib
This report presents a unique case of a vitiligo patient with concomitant systemic lupus erythematosus. Remarkably, after a 30-day course of treatment with tofacitinib, complete repigmentation of the white macular rash was achieved, and there were no adverse drug reactions. These findings provide compelling evidence for the efficacy and safety of oral JAK inhibitors, such as tofacitinib, in vitiligo treatment. Additionally, JAK inhibitors can yet be regarded as a promising new treatment option for vitiligo patients with concurrent autoimmune diseases.PMID:38524393 | PMC:PMC10961069 | DOI:10.2147/CCID.S448535 (Source: Clini...
Source: Clinical, Cosmetic and Investigational Dermatology - March 25, 2024 Category: Dermatology Authors: Qingxia Lin Jinrong Zhu Xuelei Gao Source Type: research
Platelet-rich plasma as a new and successful treatment for lichen planopilaris: A controlled blinded randomized clinical trial
CONCLUSION: Given the different efficacy profiles, PRP could be considered a new and effective choice for the treatment of LPP.PMID:38525908 | DOI:10.1111/jocd.16302 (Source: Pain Physician)
Source: Pain Physician - March 25, 2024 Category: Anesthesiology Authors: Elham Behrangi Amirhossein Akbarzadehpasha Abbas Dehghani Sona Zare Mohammadreza Ghassemi Roya Zeinali Azadeh Goodarzi Zahra Lotfi Source Type: research
A Case of Vitiligo Combined with Systemic Lupus Erythematosus Treated with Tofacitinib
This report presents a unique case of a vitiligo patient with concomitant systemic lupus erythematosus. Remarkably, after a 30-day course of treatment with tofacitinib, complete repigmentation of the white macular rash was achieved, and there were no adverse drug reactions. These findings provide compelling evidence for the efficacy and safety of oral JAK inhibitors, such as tofacitinib, in vitiligo treatment. Additionally, JAK inhibitors can yet be regarded as a promising new treatment option for vitiligo patients with concurrent autoimmune diseases.PMID:38524393 | PMC:PMC10961069 | DOI:10.2147/CCID.S448535 (Source: Clini...
Source: Clinical, Cosmetic and Investigational Dermatology - March 25, 2024 Category: Dermatology Authors: Qingxia Lin Jinrong Zhu Xuelei Gao Source Type: research
Platelet-rich plasma as a new and successful treatment for lichen planopilaris: A controlled blinded randomized clinical trial
CONCLUSION: Given the different efficacy profiles, PRP could be considered a new and effective choice for the treatment of LPP.PMID:38525908 | DOI:10.1111/jocd.16302 (Source: Pain Physician)
Source: Pain Physician - March 25, 2024 Category: Anesthesiology Authors: Elham Behrangi Amirhossein Akbarzadehpasha Abbas Dehghani Sona Zare Mohammadreza Ghassemi Roya Zeinali Azadeh Goodarzi Zahra Lotfi Source Type: research
Platelet-rich plasma as a new and successful treatment for lichen planopilaris: A controlled blinded randomized clinical trial
CONCLUSION: Given the different efficacy profiles, PRP could be considered a new and effective choice for the treatment of LPP.PMID:38525908 | DOI:10.1111/jocd.16302 (Source: Pain Physician)
Source: Pain Physician - March 25, 2024 Category: Anesthesiology Authors: Elham Behrangi Amirhossein Akbarzadehpasha Abbas Dehghani Sona Zare Mohammadreza Ghassemi Roya Zeinali Azadeh Goodarzi Zahra Lotfi Source Type: research
Plasma and peritoneal fluid cytokine profiles in patient with Essure ® implant: Towards a molecular signature?
The Essure ® contraceptive device (Bayer©, Leverkusen, Germany) was the first permanent tubal occlusion hysteroscopic implant approved by the FDA in 2002 and definitively stopped in 2018 after 750,000 procedures worldwide [1]. Many patients described adverse events, including pelvic pain, as well as general clinical symptoms such as fatigue, hair loss, psychological disorders, loss of libido, pain in joints, weight changes, and lack of concentration [2–5]. The pathogenesis is not yet understood. Several hypotheses have been proposed, such as the Systemic Nickel Allergic Syndrome (SNAS) [6,7], the Aut oimmune/Autoinflam...
Source: European Journal of Obstetrics, Gynecology, and Reproductive Biology - March 25, 2024 Category: OBGYN Authors: Lorna Garnier, Fran çois Parant, Claire Bulteau, Remi Pescarmona, Emanuele Cerruto, Stephanie Moret, Chloe Miguet-Bensouda, Erdogan Nohuz, Gautier Chene Tags: Full length article Source Type: research
Correlation of clinical and trichoscopy features with the degree of histological inflammation in lichen planopilaris and frontal fibrosing alopecia in a cross-sectional study
(Source: Journal of the American Academy of Dermatology)
Source: Journal of the American Academy of Dermatology - March 24, 2024 Category: Dermatology Authors: Carolina Oliveira Costa Fechine, Neusa Yurico Sakai Valente, Ricardo Romiti, Maryanne Makredes Senna Source Type: research
TXB-001, a newly-developed polymer-conjugated anthracycline: Significantly lower adverse effects in animal models of alopecia and hand-foot syndrome
Toxicol Appl Pharmacol. 2024 Mar 21:116912. doi: 10.1016/j.taap.2024.116912. Online ahead of print.ABSTRACTAnthracycline anti-cancer drugs have been widely used in the treatment of several cancers; however, their use is limited by adverse effects (AEs). Alopecia is a common AE that is minimally invasive, but adversely affects mental health and reduces quality of life (QoL). Hand-foot syndrome (HFS) is a dose-limiting AE of DOXIL, a liposomal formulation of doxorubicin (DOX). Although it is not a life-threatening condition, HFS affects function and reduces QoL. TXB-001 is a new candidate polymer-conjugated anthracycline ant...
Source: Toxicology and Applied Pharmacology - March 23, 2024 Category: Toxicology Authors: Mikito Hirakata Emi Tomikawa Chizuka Sakai Masashi Uchida Tsubasa Okano Reiko Shimozono Masakatsu Kawai Shoichi Itaba Lisa Munakata Ryo Suzuki Keiyu Oshida Source Type: research
TXB-001, a newly-developed polymer-conjugated anthracycline: Significantly lower adverse effects in animal models of alopecia and hand-foot syndrome
Toxicol Appl Pharmacol. 2024 Mar 21:116912. doi: 10.1016/j.taap.2024.116912. Online ahead of print.ABSTRACTAnthracycline anti-cancer drugs have been widely used in the treatment of several cancers; however, their use is limited by adverse effects (AEs). Alopecia is a common AE that is minimally invasive, but adversely affects mental health and reduces quality of life (QoL). Hand-foot syndrome (HFS) is a dose-limiting AE of DOXIL, a liposomal formulation of doxorubicin (DOX). Although it is not a life-threatening condition, HFS affects function and reduces QoL. TXB-001 is a new candidate polymer-conjugated anthracycline ant...
Source: Toxicology and Applied Pharmacology - March 23, 2024 Category: Toxicology Authors: Mikito Hirakata Emi Tomikawa Chizuka Sakai Masashi Uchida Tsubasa Okano Reiko Shimozono Masakatsu Kawai Shoichi Itaba Lisa Munakata Ryo Suzuki Keiyu Oshida Source Type: research
Cronkhite-Canada syndrome with esophagus involvement and six-year follow-up: A case report
CONCLUSION: Comprehensive treatment led by hormonal therapy can result in partial or full remission of clinical symptoms. Treatment should be individualized for each patient according to their therapy response. Surveillance endoscopy is necessary for assessing mucosal disease activity and detecting malignant transformation.PMID:38516236 | PMC:PMC10950646 | DOI:10.3748/wjg.v30.i8.984 (Source: World Journal of Gastroenterology : WJG)
Source: World Journal of Gastroenterology : WJG - March 22, 2024 Category: Gastroenterology Authors: Yu-Chen Tang Source Type: research
